Measuring MRD in CLL
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical implications of measuring minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL). Dr Wierda outlines how MRD is useful in a practical setting as well as within clinical trial design and monitoring as a measure of progression-free survival and overall survival. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
